journal
MENU ▼
Read by QxMD icon Read
search

Journal of Oncology Pharmacy Practice

journal
https://www.readbyqxmd.com/read/27824586/persistently-curly-hair-phenotype-with-the-use-of-nivolumab-for-squamous-cell-lung-cancer
#1
Constantin A Dasanu, Scott M Lippman, Steven C Plaxe
Increasing use of programmed cell death protein 1/programmed cell death protein 1 ligand inhibition for the treatment of patients with various malignancies such as advanced lung cancer, kidney cancer, and melanoma has resulted in valuable clinical responses, along with the occurrence of new and often puzzling side effects. Known cutaneous effects of CTLA4 and programmed cell death protein 1/programmed cell death protein 1 ligand inhibitors include generalized pruritus, vitiligo, maculopapular lesions, and lichenoid skin eruptions...
December 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27753628/study-of-cases-of-abiraterone-discontinuation-due-to-toxicity-in-pre-chemotherapy-after-1-year-s-experience
#2
Luis Ramudo-Cela, Jesús Balea-Filgueiras, José Ramón Vizoso-Hermida, Isabel Martín-Herranz
Abiraterone acetate is a potent and irreversible inhibitor of cytochrome p450 17A1 that suppresses androgen synthesis. It is approved for chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. We describe the protocol for use of abiraterone in metastatic castration-resistant prostate cancer chemotherapy naive patients has been implanted in our centre and we review the cases of those patients whose adverse effects have forced the discontinuation of treatment. The side effects fit the safety profile of abiraterone, speed of their appearance and severity indicate that you should perform a thorough follow-up of these patients especially in the early phases of treatment...
December 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27664112/plasma-levels-of-trastuzumab-in-gastric-cancer-case-report
#3
J González-García, B Alonso-Alvarez, G J Nazco-Casariego, N Batista-López, F Guttiérrez-Nicolás
Introduction The use of trastuzumab with a fluoropyrimidine and platinum compound is currently the standard first-line treatment of patients with metastatic HER2-positive gastric cancer, but it appears that serum levels of trastuzumab determine the clinical effectiveness of this treatment, affecting progression-free survival and overall survival. Case report We report the case of a patient with metastatic HER2-positivegastric cancer, receiving XELOX (fluoropyrimidine and oxaliplatin) plus trastuzumab at standard doses, who presented sub-therapeutic serum levels during the first two treatment cycles and rapid disease progression (progression-free survival = 5...
December 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27609337/nivolumab-induced-vitiligo-in-a-metastatic-melanoma-patient-a-case-report
#4
Lindsay A Edmondson, Leticia V Smith, Alka Mallik
The programmed-death-1 inhibitors selectively block programmed-death-1 interaction with its receptor, which restores active T-cell response directed at tumor cells, inducing an anti-tumor effect. This nonspecific activation of the immune system can also lead to a wide spectrum of side effects. Nivolumab has been used effectively to prolong survival in patients with metastatic melanoma and is recommended as a category 1 agent for systemic therapy in metastatic or unresectable melanoma per the National Comprehensive Cancer Network guidelines...
December 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27609336/impact-of-a-clinical-pathway-on-appropriate-empiric-vancomycin-use-in-cancer-patients-with-febrile-neutropenia
#5
Mildred Vicente, Mohammad Al-Nahedh, Sandeep Parsad, Randall W Knoebel, Jennifer Pisano, Natasha N Pettit
Objectives Febrile neutropenia management guidelines recommend the use of vancomycin as part of an empiric antimicrobial regimen when specific criteria are met. Often, vancomycin use among patients with febrile neutropenia is not indicated and may be over utilized for this indication. We sought to evaluate the impact of implementing a febrile neutropenia clinical pathway on empiric vancomycin use for febrile neutropenia and to identify predictors of vancomycin use when not indicated. Methods Adult febrile neutropenia patients who received initial therapy with an anti-pseudomonal beta-lactam with or without vancomycin were identified before (June 2008 to November 2010) and after (June 2012 to June 2013) pathway implementation...
December 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27604142/concurrent-gastrointestinal-perforation-and-pulmonary-embolism-due-to-bevacizumab-in-an-adult-undergoing-treatment-for-stage-iv-colon-cancer
#6
Sana Qureshi, Ryan B Elliott, Jon D Herrington
Bevacizumab is an important component in the treatment of metastatic colorectal cancer when used with 5-fluorouracil, leucovorin and oxaliplatin or irinotecan. As a molecular target agent, it is considered to be less toxic than traditional chemotherapy; however, bevacizumab has been shown to cause serious, life-threatening adverse effects. The following report describes a case of bevacizumab-associated pulmonary embolism with simultaneous gastrointestinal perforation in a patient with stage IV adenocarcinoma of the descending colon...
December 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27590328/sarcoidosis-like-syndrome-and-lymphadenopathy-due-to-checkpoint-inhibitors
#7
Belal Firwana, Rahul Ravilla, Mihir Raval, Laura Hutchins, Fade Mahmoud
Immunotherapy with checkpoint inhibitors has revolutionized the management of metastatic melanoma. These checkpoints, namely the cytotoxic T lymphocyte antigen 4 and the programmed T cell death 1 receptor, possess an inhibitory effect on the T cell function. Pharmacologic inhibition of cytotoxic T lymphocyte antigen 4 with ipilimumab and programmed T cell death 1 with either pembrolizumab or nivolumab has resulted in long-term sustained responses among patients with metastatic melanoma. The adverse events of these medications are predominantly immune related...
December 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27573921/evaluation-of-electronic-health-record-implementation-on-pharmacist-interventions-related-to-oral-chemotherapy-management
#8
Anastasia Finn, Carolyn Bondarenka, Kathy Edwards, Rebekah Hartwell, Cathy Letton, Andy Perez
Background With the ever growing arsenal of oral chemotherapy agents now available, cancer treatment is being increasingly managed in the outpatient setting. However, oral chemotherapy use is often associated with several potential obstacles and complications. In order to provide optimal patient safety and oral chemotherapy monitoring, our institution implemented an oral chemotherapy program managed by clinical pharmacists electronically through Epic Beacon. Objective To describe implementation of a novel pharmacist-managed oral chemotherapy program and evaluate pharmacist interventions before and after implementation of an oral chemotherapy program...
December 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28791909/it-takes-a-village-to-raise-awareness-of-and-to-address-surface-contamination-of-hazardous-drugs
#9
William C Zamboni, Stephanie A Salch, Joshua Cox, Stephen Eckel
No abstract text is available yet for this article.
October 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28764597/letters-about-published-papers
#10
Jim Siderov
No abstract text is available yet for this article.
October 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27559020/a-rare-case-of-blastic-plasmacytoid-dendritic-cell-neoplasm-with-deletion-7q-31-in-the-setting-of-heavy-pre-treatment-with-alkylating-chemotherapy
#11
Varinder Kaur, Arjun Swami, Atrash Shebli, Sara Shalin, Muthu Veeraputhiran, Peter Emanuel, Yogesh Jethava
Blastic plasmacytoid dendritic cell neoplasm is rare myeloid malignancy clinically characterized by non-pruritic, violaceous and papulo-nodular skin lesions, together with bone marrow and lymph node involvement. Histologically, there is infiltration of dermis by neoplastic mono-nuclear CD4, CD56, CD123 co-expressing cells with epidermal sparing. Most commonly blastic plasmacytoid dendritic cell neoplasm presents as a de-novo condition, and treatment-related blastic plasmacytoid dendritic cell neoplasm is a rare phenomenon...
October 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27543094/effect-of-single-agent-high-dose-methotrexate-related-acute-kidney-injury-on-length-of-hospitalization-and-relative-dose-intensity-in-adult-patients-with-central-nervous-system-lymphoma
#12
Jennifer S Steward, Heather M Bullard, Timothy J O'Rourke, Alan D Campbell, Brett T Brinker, Kathleen J Yost, Amy C Vanderwoude, William L Scott, Polly E Kintzel
Purpose Grade ≥3 adverse effects prolong hospitalization and reduce chemotherapy dose intensity. The purpose of this study was to evaluate the rate and severity of high-dose methotrexate-related acute kidney injury and analyze its effect on hospital length of stay and relative chemotherapy dose intensity. Methods This was a retrospective cohort analysis. Patients receiving ≥1 dose of high-dose methotrexate were analyzed for acute kidney injury and length of stay. Patients receiving ≥6 cycles of induction therapy were included in the analysis of relative chemotherapy dose intensity...
October 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27530243/drug-drug-interactions-of-cytostatics-with-regular-medicines-in-lung-cancer-patients
#13
Florentine Mv Rompelman, Adrianus Aj Smit, Eric Jf Franssen, Mirjam Crul
Background Lung cancer patients have a high risk for drug-drug interactions, as they use numerous types of concomitant medicines including antineoplastic agents, cancer treatment co-medication, and medicines aimed at several types of comorbidities. Objective The primary objective of this study is to determine the incidence and the clinical relevance of the drug-drug interactions between antineoplastic agents and regular medication used by lung cancer patients. Secondary objectives are (i) to determine the effectiveness of the medication review by the hospital pharmacists concerned, (ii) to establish which patients are most at risk of drug-drug interactions and (iii) to determine whether physicians comply with advice given by hospital pharmacists...
October 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27530242/paclitaxel-pre-medication-a-comparison-of-two-steroid-pre-medication-protocols
#14
Ayberk Yenilmez, Annette P Hood, Lien H Nguyen, Man Y Merl
Purpose To evaluate and compare the rate of hypersensitivity reactions between two low-dose steroid pre-medication regimens for paclitaxel-based treatments. Methods This was a single-center, retrospective, descriptive study, comparing the incidence of hypersensitivity reactions in two different dexamethasone pre-medication regimens that took place between July 2013 to December 2014. Patients who were paclitaxel-naïve with a diagnosis of breast or gynecological cancers were included. Patients in the early termination protocol were pre-medicated with a standard pre-medication regimen and if tolerated with no hypersensitivity reaction occurrence, all pre-medications were discontinued after the first two infusions...
October 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27511215/sustained-clinico-radiologic-response-to-anti-cytotoxic-t-lymphocyte-antigen-4-antibody-therapy-in-metastatic-myxoid-liposarcoma
#15
Constantin A Dasanu
Rarity and heterogeneity of sarcomas pose significant challenges in terms of developing new therapies. Therefore, efforts towards studying immunotherapy in sarcomas may provide hope for effective control of this group of devastating cancers. A sustained clinico-radiologic response to the anti-cytotoxic T lymphocyte antigen 4 antibody ipilimumab in a patient with metastatic myxoid liposarcoma is reported. Although the patient was treated with this agent for metastatic melanoma, both his metastatic cancers - melanoma and sarcoma - meaningfully responded to this agent...
October 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27466225/safe-administration-of-docetaxel-after-weekly-paclitaxel-induced-acute-pancreatitis
#16
Jean-Philippe Adam, Philippe Gauthier, Nathalie Letarte
Acute pancreatitis is an inflammatory process of the pancreas that can be mild to severe. It requires biochemical or radiologic evidence to establish the diagnosis. Only few chemotherapy agents are directly linked to acute pancreatitis. In this case report, we describe a patient who developed a mild acute pancreatitis on weekly paclitaxel with a positive dechallenge and rechallenge. A 57-year-old woman with advanced ovarian cancer started chemotherapy with carboplatin (AUC 5 every three weeks) and weekly paclitaxel (80 mg/m(2) on days 1, 8, and 15)...
October 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27388159/utilization-and-evaluation-of-noncore-chemotherapy-regimens-within-an-academic-medical-center
#17
Jason R Jared, Mary S Mably, Rory Makielski, Michael P Reed, Michael J Fallon, Glenn Liu, Daniel Mulkerin, Natalie S Callander
Uniformity of evidence-based chemotherapy prescribing using approved, standard, or "core" regimens provides systems-based safety. Noncore chemotherapy regimens are non-standard-of-care regimens requested by physicians on a patient-by-patient basis. Chemotherapy Council, a Pharmacy & Therapeutics subcommittee, assesses all requests and determines approval status based upon submitted evidence and patient-specific factors. This study's purpose is to describe noncore chemotherapy regimens utilization, efficacy, and clinical outcomes in patients receiving noncore chemotherapy regimens...
October 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27357816/expanding-the-armamentarium-for-chronic-lymphocytic-leukemia-a-review-of-novel-agents-in-the-management-of-chronic-lymphocytic-leukemia
#18
Bernard L Marini, Lisa Samanas, Anthony J Perissinotti
Treatment options for chronic lymphocytic leukemia, the most common leukemia in the United States, have expanded rapidly in recent years. While traditional chemoimmunotherapy still remains a mainstay for young, fit patients, a number of novel targeted therapies have emerged that have changed the therapeutic landscape. Two innovative anti-CD20 monoclonal antibodies, obinutuzumab and ofatumomamab, have demonstrated activity in chronic lymphocytic leukemia and represent well-tolerated options in upfront management of elderly patients or in those with significant comorbidities...
October 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27357815/bortezomib-therapy-related-lung-disease-in-a-patient-with-light-chain-amyloidosis-a-case-report
#19
Erich Balsman
Bortezomib was the first antineoplastic proteasome inhibitor and is currently indicated for the treatment of hematologic malignancies including multiple myeloma and mantle cell lymphoma. This report describes a 57-year-old patient with light chain (primary) amyloidosis receiving weekly subcutaneous bortezomib injections who presented with recurrent hypoxemia and interstitial pneumonitis. Following the failure of conventional therapy, the patient responded rapidly to high-dose intravenous methylprednisolone...
October 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27306885/evolution-of-ramucirumab-in-the-treatment-of-cancer-a-review-of-literature
#20
A Vennepureddy, P Singh, R Rastogi, J P Atallah, T Terjanian
Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. Its mechanism of action is by inhibiting angiogenesis in tumor cells by targeting the vascular endothelial growth factor receptor 2. United States Food and Drug Administration (FDA) approved it initially in 2014 for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma and metastatic non-small cell lung carcinoma. It was approved by FDA in 2015 for the treatment of advanced colorectal cancer...
October 2017: Journal of Oncology Pharmacy Practice
journal
journal
32324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"